


CB-103

## Chemical Properties

CAS No. : 218457-67-1  
 Formula: C<sub>15</sub>H<sub>18</sub>N<sub>2</sub>O  
 Molecular Weight: 242.32  
 Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year  
 Actual storage temperature shall be subject to the COA.



## Biological Description

Description	CB-103 is a orally active inhibitor of notch signaling pathway, with anti-tumor activity.
Targets(IC50)	Gamma-secretase
In vitro	CB-103 has shown the ability to block NOTCH signaling in human T cell acute lymphoblastic leukemia cancer cell lines, and exhibits anti-tumor efficacy in GSI resistant T-ALL cell lines[2].
In vivo	CB-103inhibits growth of GSI/Mab resistant triple negative breast cancer, andexhibits anti-tumor activity in xenograft models of human T-ALL and mouse mammary tumors [3].

## Solubility Information

Solubility	DMSO: 50 mg/mL (206.34 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween-80+45% Saline: 2.5 mg/mL (10.32 mM),Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

### Preparing Stock Solutions

---

	1mg	5mg	10mg
1 mM	4.1268 mL	20.6339 mL	41.2677 mL
5 mM	0.8254 mL	4.1268 mL	8.2535 mL
10 mM	0.4127 mL	2.0634 mL	4.1268 mL
50 mM	0.0825 mL	0.4127 mL	0.8254 mL

---

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

- Freddy Radtke, et al. Inhibitors of notch signalling pathway and use thereof in treatment of cancers. US9296682B2.  
R.Lehal, et al. Development of a novel first-in-class oral inhibitor of the NOTCH pathway.  
Rajwinder Lehal, et al. Non clinical pharmacology, pharmacokinetics and safety profiling of CB-103: A novel first-in-class small molecule inhibitor of the NOTCH pathway.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481